146
Views
4
CrossRef citations to date
0
Altmetric
Review

Precision medicine and personalized breast cancer: combination pertuzumab therapy

, , &
Pages 95-105 | Published online: 20 Mar 2014

Figures & data

Figure 1 Schema outlining the activation of the human epidermal growth-factor receptor 2 pathway and antibody blockade by trastuzumab and pertuzumab.

Abbreviations: HER, human epidermal growth-factor receptor; FGFR, fibroblast growth-factor receptor; IGFR, insulin-like growth-factor receptor; IV, intravenous; PI3K, phosphoinositide 3-kinase; MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated kinase; mTOR, mammalian target of rapamycin.
Figure 1 Schema outlining the activation of the human epidermal growth-factor receptor 2 pathway and antibody blockade by trastuzumab and pertuzumab.

Table 1 Key randomized clinical trials evaluating pertuzumab therapy for HER2-positive breast cancer

Figure 2 Schema of the NeoSphere clinical trial comparing various neoadjuvant HER2-directed therapies for localized HER2-positive breast cancer.

Abbreviations: HER, human epidermal growth-factor receptor; pCR, pathological complete response.
Figure 2 Schema of the NeoSphere clinical trial comparing various neoadjuvant HER2-directed therapies for localized HER2-positive breast cancer.

Figure 3 Schema of the APHINITY clinical trial evaluating efficacy of adjuvant pertuzumab based therapy in localized HER2-positive breast cancer.

Notes: aTrastuzumab 6 mg/kg IV q3 weeks, pertuzumab 420 mg IV q3 weeks; beither anthracycline-based regimen with a taxane, or Taxotere with carboplatin; cHER2 therapy for 1 year (52 weeks).
Abbreviations: HER, human epidermal growth-factor receptor; IV, intravenous; q3 weeks, every 3 weeks; APHINITY, Adjuvant Pertuzumab and Herceptin in Initial Therapy of Breast Cancer.
Figure 3 Schema of the APHINITY clinical trial evaluating efficacy of adjuvant pertuzumab based therapy in localized HER2-positive breast cancer.

Table 2 Pertuzumab-based chemotherapy regimens as per the US Food and Drug Administration prescribing label (updated September 2013)

Figure 4 Schema of personalized therapy selection based on molecular profiling of breast cancer.

Notes: The purpose of this figure to provide a conceptual framework of how trastuzumab and pertuzumab would form the backbone of personalized HER2-directed therapy. It is not meant to be inclusive of all possible therapies or combinations. The various inhibitors are being investigated in clinical trials, and are not currently the standard of care. *± Chemotherapy, and endocrine therapy if HR positive.
Abbreviations: PI3K, phosphoinositide 3-kinase; HER, human epidermal growth-factor receptor; FGFR, fibroblast growth-factor receptor; HR, hormone receptor.
Figure 4 Schema of personalized therapy selection based on molecular profiling of breast cancer.